Bioxyne Secures 12-Month Manufacturing Contract with Aurora Cannabis for Cannabis Oils and Vapes

A Strategic Alliance in Medicinal Cannabis Manufacturing

Australian biotech company Bioxyne Ltd, through its subsidiary Breathe Life Sciences (BLS), has entered into a significant manufacturing agreement with Aurora Cannabis, a leading global player in the medical cannabis sector. This partnership not only validates Bioxyne’s expertise in producing GMP-certified medicinal cannabis products but also signals its growing footprint on the international stage.

The initial phase of the agreement focuses on supplying pharmaceutical-grade medicinal cannabis oils into the Australian market, with initial deliveries already completed. This milestone confirms Bioxyne’s capability to meet stringent regulatory standards and supply chain demands in a highly regulated industry.

Expanding Product Range and Market Reach

Building on the initial success, the agreement is set to expand to include the manufacture of GMP-certified cannabis vapes. These products will be distributed not only in Australia but also in key international markets including the United Kingdom and Germany. This expansion reflects both companies’ ambitions to capture growth opportunities in multiple jurisdictions where medical cannabis demand is rising.

Bioxyne’s CEO, Sam Watson, highlighted the significance of this deal, describing it as a major milestone that enhances the company’s manufacturing capabilities and validates its pharmaceutical-grade expertise. Aurora’s Executive Vice President of Operations & Supply Chain, Alex Miller, emphasised the importance of a resilient and high-quality supply chain, underscoring the strategic fit between the two companies.

Implications for Bioxyne and the Broader Market

The 12-month rolling term of the agreement, with automatic renewal and a six-month termination notice, provides Bioxyne with a stable platform for growth and ongoing collaboration. This partnership positions BLS as a trusted supplier capable of meeting the complex demands of international medical cannabis markets, which are characterised by rigorous quality and regulatory requirements.

Moreover, Bioxyne’s expanding manufacturing footprint across Australia, the UK, Germany, Japan, and Europe, combined with its portfolio of controlled substances including cannabis, MDMA, and psilocybin, underscores its ambition to be a global leader in alternative therapeutics and investigational medicines.

While financial details remain undisclosed, the deal is expected to enhance Bioxyne’s revenue streams and market credibility. However, navigating the regulatory landscapes across multiple countries will require continued diligence and adaptability.